These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 26022200)

  • 1. Peptidomimetic furin inhibitor MI-701 in combination with oseltamivir and ribavirin efficiently blocks propagation of highly pathogenic avian influenza viruses and delays high level oseltamivir resistance in MDCK cells.
    Lu Y; Hardes K; Dahms SO; Böttcher-Friebertshäuser E; Steinmetzer T; Than ME; Klenk HD; Garten W
    Antiviral Res; 2015 Aug; 120():89-100. PubMed ID: 26022200
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Neuraminidase amino acids 149 and 347 determine the infectivity and oseltamivir sensitivity of pandemic influenza A/H1N1 (2009) and avian influenza A/H5N1.
    Yongkiettrakul S; Nivitchanyong T; Pannengpetch S; Wanitchang A; Jongkaewwattana A; Srimanote P
    Virus Res; 2013 Aug; 175(2):128-33. PubMed ID: 23639424
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of double combinations of amantadine, oseltamivir, and ribavirin on influenza A (H5N1) virus infections in cell culture and in mice.
    Smee DF; Hurst BL; Wong MH; Bailey KW; Morrey JD
    Antimicrob Agents Chemother; 2009 May; 53(5):2120-8. PubMed ID: 19273672
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Analysis of influenza viruses from patients clinically suspected of infection with an oseltamivir resistant virus during the 2009 pandemic in the United States.
    Nguyen HT; Trujillo AA; Sheu TG; Levine M; Mishin VP; Shaw M; Ades EW; Klimov AI; Fry AM; Gubareva LV
    Antiviral Res; 2012 Mar; 93(3):381-6. PubMed ID: 22330888
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Identification of Indonesian clade 2.1 highly pathogenic influenza A(H5N1) viruses with N294S and S246N neuraminidase substitutions which further reduce oseltamivir susceptibility.
    McKimm-Breschkin JL; Barrett S; Wong FYK; Pudjiatmoko ; Azhar M; Selleck P; Davies KR; Hartaningsih N; McGrane J
    Antiviral Res; 2018 May; 153():95-100. PubMed ID: 29574145
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Triple combination of amantadine, ribavirin, and oseltamivir is highly active and synergistic against drug resistant influenza virus strains in vitro.
    Nguyen JT; Hoopes JD; Le MH; Smee DF; Patick AK; Faix DJ; Blair PJ; de Jong MD; Prichard MN; Went GT
    PLoS One; 2010 Feb; 5(2):e9332. PubMed ID: 20179772
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A single E105K mutation far from the active site of influenza B virus neuraminidase contributes to reduced susceptibility to multiple neuraminidase-inhibitor drugs.
    Fujisaki S; Takashita E; Yokoyama M; Taniwaki T; Xu H; Kishida N; Sato H; Tashiro M; Imai M; Odagiri T
    Biochem Biophys Res Commun; 2012 Dec; 429(1-2):51-6. PubMed ID: 23131559
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Host cell selection of influenza neuraminidase variants: implications for drug resistance monitoring in A(H1N1) viruses.
    Okomo-Adhiambo M; Nguyen HT; Sleeman K; Sheu TG; Deyde VM; Garten RJ; Xu X; Shaw MW; Klimov AI; Gubareva LV
    Antiviral Res; 2010 Feb; 85(2):381-8. PubMed ID: 19917319
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Triple combination of oseltamivir, amantadine, and ribavirin displays synergistic activity against multiple influenza virus strains in vitro.
    Nguyen JT; Hoopes JD; Smee DF; Prichard MN; Driebe EM; Engelthaler DM; Le MH; Keim PS; Spence RP; Went GT
    Antimicrob Agents Chemother; 2009 Oct; 53(10):4115-26. PubMed ID: 19620324
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Neuraminidase mutations conferring resistance to laninamivir lead to faster drug binding and dissociation.
    McKimm-Breschkin JL; Barrett S
    Antiviral Res; 2015 Feb; 114():62-6. PubMed ID: 25499124
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mycophenolic mofetil, an alternative antiviral and immunomodulator for the highly pathogenic avian influenza H5N1 virus infection.
    Cho J; Yi H; Jang EY; Lee MS; Lee JY; Kang C; Lee CH; Kim K
    Biochem Biophys Res Commun; 2017 Dec; 494(1-2):298-304. PubMed ID: 29017920
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Assessing the development of oseltamivir and zanamivir resistance in A(H5N1) influenza viruses using a ferret model.
    Hurt AC; Lowther S; Middleton D; Barr IG
    Antiviral Res; 2010 Sep; 87(3):361-6. PubMed ID: 20603155
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Therapeutic efficacy of peramivir against H5N1 highly pathogenic avian influenza viruses harboring the neuraminidase H275Y mutation.
    Kobayashi M; Kodama M; Noshi T; Yoshida R; Kanazu T; Nomura N; Soda K; Isoda N; Okamatsu M; Sakoda Y; Yamano Y; Sato A; Kida H
    Antiviral Res; 2017 Mar; 139():41-48. PubMed ID: 28012921
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comprehensive assessment of 2009 pandemic influenza A (H1N1) virus drug susceptibility in vitro.
    Gubareva LV; Trujillo AA; Okomo-Adhiambo M; Mishin VP; Deyde VM; Sleeman K; Nguyen HT; Sheu TG; Garten RJ; Shaw MW; Fry AM; Klimov AI
    Antivir Ther; 2010; 15(8):1151-9. PubMed ID: 21149922
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Influenza viruses resistant to neuraminidase inhibitors.
    Nitsch-Osuch A; Brydak LB
    Acta Biochim Pol; 2014; 61(3):505-8. PubMed ID: 25195142
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Neuraminidase Mutations Conferring Resistance to Oseltamivir in Influenza A(H7N9) Viruses.
    Marjuki H; Mishin VP; Chesnokov AP; De La Cruz JA; Davis CT; Villanueva JM; Fry AM; Gubareva LV
    J Virol; 2015 May; 89(10):5419-26. PubMed ID: 25740997
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The effect of the MDCK cell selected neuraminidase D151G mutation on the drug susceptibility assessment of influenza A(H3N2) viruses.
    Mishin VP; Sleeman K; Levine M; Carney PJ; Stevens J; Gubareva LV
    Antiviral Res; 2014 Jan; 101():93-6. PubMed ID: 24239666
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Oseltamivir-ribavirin combination therapy for highly pathogenic H5N1 influenza virus infection in mice.
    Ilyushina NA; Hay A; Yilmaz N; Boon AC; Webster RG; Govorkova EA
    Antimicrob Agents Chemother; 2008 Nov; 52(11):3889-97. PubMed ID: 18725448
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In vitro activity of favipiravir and neuraminidase inhibitor combinations against oseltamivir-sensitive and oseltamivir-resistant pandemic influenza A (H1N1) virus.
    Tarbet EB; Vollmer AH; Hurst BL; Barnard DL; Furuta Y; Smee DF
    Arch Virol; 2014 Jun; 159(6):1279-91. PubMed ID: 24311151
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Drug susceptibility of influenza A/H3N2 strains co-circulating during 2009 influenza pandemic: first report from Mumbai.
    Gohil DJ; Kothari ST; Shinde PS; Chintakrindi AS; Meharunkar R; Warke RV; Kanyalkar MA; Chowdhary AS; Deshmukh RA
    Infect Genet Evol; 2015 Jan; 29():75-81. PubMed ID: 25461259
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.